

### **REMARKS**

Claims 1-32 are cancelled and new claims 33-40 are added. In response to the restriction requirement, Applicants hereby elect the Group I invention drawn to a method of sequencing. New claims are drawn to a method sequencing nucleic acid and therefore should be included within Group I.

#### **Support for Claim Amendments**

New claims 33-40 have been added.

Claim 33 is drawn to "a method for sequencing nucleic acid." Support for new claim 33 is found throughout the specification, for example, in claims 1-3 as originally filed and in paragraphs [0015], [0103] and [0105] of the published application.

Claim 34 is drawn to a method of claim 33, wherein said amplifying step comprises polymerase chain reaction (PCR) amplification. Support for new claim 34 is found throughout the specification, for example, in paragraph [0052] of the published application.

Claim 35 is drawn to a method of claim 33, wherein said amplifying step comprises cloning. Support for new claim 35 is found throughout the specification, for example, in paragraph [0040] of the published application.

Claim 36 is drawn to a method of claim 33, further comprising immobilizing said one or more duplexes on a substrate. Support for new claim 36 is found throughout the specification, for example, in paragraph [0051] of the published application.

Claim 37 is drawn to a method of claim 36, wherein said one or more duplexes are immobilized such that said one or more duplexes are individually optically resolvable on said substrate. Support for new claim 37 is found throughout the specification, for example, in paragraph [0084] of the published application.

Claim 38 is drawn to a method of claim 33, wherein said detectable label is an optically-detectable label. Claim 39 is drawn to a method of claim 38, wherein said optically-detectable label is a fluorescent label. Claim 40 is drawn to a method of claim 38, wherein said optically-detectable label is a chemiluminescent label. Support for new

claims 38-40 is found throughout the specification, for example, in claims 2 and 3 as originally filed and in paragraph [0015] of the published application.

**CONCLUSION**

If the Examiner believes a conversation with Applicants' representative would be helpful in expediting prosecution of this application, the Examiner is invited to the call the undersigned at the number below.

Respectfully submitted,



Sandra A. Brockman-Lee  
Attorney for the Applicants  
Proskauer Rose LLP  
One International Place  
Boston, MA 02110

Date: April 26, 2007

Reg. No.: 44,045

Tel. No.: (617) 526-9617

Fax No.: (617) 526-9899